| Abstract |
Objective Through the comparision of berberine and metformin in the treatment of lipid index and HOMA-IR in schizophrenia with metabolic syndrome, to investigate the effect of berberine, and explore the relationship with insulin resistance. Methods A total of 89 schizophrenia patients with olanzapine treatment were divided into two groups: 43 study group(treated with olanzapine combined with berberine) and 46 control group(treated with olanzapine combined with metformin) for 12 weeks. The body weight, BMI, FPG, Fins, TC, TG, APN, LEP were evaluated before and after the treatment. The homeostasis model assessment for HOMA-IR was calculated. In addition, the treatment emergent symptom scale (TESS) was assessed adverse reactions. Results Compared with before treatment, both groups had significantly improved in body weight, BMI, TC, TG, APN, LEP, and HOMA-IR in 12th week (P<0.01). All the indices between two groups had no significant difference post-treatment (P>0.05). The HOMA-IR in study group was positively correlated with TC, TG, LEP changing value (P<0.05), and negatively correlated with APN changing value (P<0.05). There were no significant differences on adverse reactions between the two groups (P>0.05). Conclusion Berberine has significant efficacy on weight loss, lipids metabolic abnormalities in patients with schizophrenia and MS, and has the same efficacy as metformin. This maybe associated with insulin resistance.
|